Project Grant R21AI181224

Award Date 5/21/24
Completion Date 3/31/26
Dollars Obligated $876K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $741,917 in funding to the West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives of this 5-year project are to: 1) characterize the mechanism of action of a lead antibody...
This federal Project Grant award of $895,538 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop shorter and more effective oral regimens for treating Mycobacterium abscessus pulmonary disease. The research team, led by HMH Hospitals Corporation (doing business as Hackensack University Medical Center), will pursue complementary approaches to discover all-oral sterilizing...
This $794,849 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Cedars-Sinai Medical Center to investigate mechanisms of cefiderocol resistance and develop approaches to improve the potency and limit the development of resistance to this antibiotic. The key objectives are to: 1) determine how mutations in the CpxS regulator affect efflux pump expression and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of regulatory T cells (Tregs) in protecting against Pseudomonas aeruginosa lung infections. The $239,348 award, spanning from November 2024 to October 2026, will enable researchers at Columbia University's Health Sciences Division to evaluate how Tregs alter the airway metabolome to...
This $868,776 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to characterize a novel post-transcriptional regulator in the pathogenic bacterium Pseudomonas aeruginosa. The award, spanning from February 2025 to January 2030, aims to: Identify the direct regulatory targets of the RNA-binding protein PHAF in P. aeruginosa under different growth conditions,...
This $849,713 Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports research to elucidate RNA-RNA interaction networks during interbacterial interactions involving the bacterium Pseudomonas aeruginosa. The research team at Boston Children's Hospital seeks to define the small RNA (sRNA) interaction network in P. aeruginosa and decode the regulatory roles played by sRNAs during its interactions with other bacteria. The project will...
This National Institutes of Health National Heart Lung and Blood Institute project grant of $460,175.84 supports research into the effects of acidosis on pneumonia through December 31, 2021. The award funds a study at the University of South Alabama examining how the carbonic anhydrase IX isoform and cytotoxic amyloid proteins impact pulmonary endothelial cell function during Pseudomonas aeruginosa infection. Specifically, the research will test the hypotheses that CA IX is critical to acid...
This $569,210 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize key enzymes responsible for lipid A modification, a mechanism that confers antibiotic resistance in certain gram-negative bacteria. The project aims to develop inhibitors targeting these enzymes, which could potentiate the efficacy of the antibiotic colistin against deadly...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate how the pathogen Pseudomonas aeruginosa causes urinary tract infections (UTIs) and whether age influences infection establishment and persistence. The $1,010,671 award to Vanderbilt University Medical Center (VUMC) will support research to define how specific genomic features in uropathogenic...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $1,117,491 over 5 years to support research on bacterial stress responses and surface adhesion in shear flow. The research, conducted at the University of Illinois, combines traditional molecular biology approaches with microfluidic technology to examine how host-relevant shear flow impacts stress responses and surface adhesion of the...

SURFACE DEPENDENT INHIBITION OF MYCOBACTERIUM ABSCESSUS BY PSEUDOMONAS AERUGINOSA - PROJECT ABSTRACT TREATMENT OF BIOFILM-ASSOCIATED INFECTIONS, SUCH AS THOSE CAUSED BY PSEUDOMONAS AERUGINOSA AND NON- TUBERCULOUS MYCOBACTERIA (NTM), CAN BE EXTREMELY CHALLENGING, ESPECIALLY WHEN THESE INFECTIOUS AGENTS CO- INFECT THE LUNGS OF PEOPLE WITH CYSTIC FIBROSIS (CF) OR OTHER DISEASES. THIS APPLICATION SEEKS TO UNDERSTAND COMMUNITY INTERACTIONS BETWEEN P. AERUGINOSA AND THE ANTIBIOTIC RESISTANT NTM MYCOBACTERIUM ABSCESSUS. P. AERUGINOSA AND M. ABSCESSUS ARE BOTH FOUND IN THE SAME ENVIRONMENTAL RESERVOIRS AND ARE CO-ISOLATED FROM INDIVIDUALS WITH CF AND SURGICAL SITE/SOFT TISSUE INFECTIONS. INDEED, STUDIES DEMONSTRATE THAT M. ABSCESSUS POSITIVE CF INDIVIDUALS ARE MORE LIKELY TO BE INFECTED WITH P. AERUGINOSA. DESPITE THIS, THERE IS LIMITED UNDERSTANDING OF THE INTERACTION BETWEEN THESE TWO IMPORTANT OPPORTUNISTIC PATHOGENS. WE RECENTLY INVESTIGATED M. ABSCESSUS AND P. AERUGINOSA INTERACTIONS AND REPORTED SEVERAL NOVEL OBSERVATIONS. P. AERUGINOSA POTENTLY ANTAGONIZES BOTH ROUGH AND SMOOTH M. ABSCESSUS VARIANTS, YET ONLY WHEN CO-CULTURED IN DUAL-SPECIES BIOFILMS; ANTAGONISM WAS NOT OBSERVED IN PLANKTONIC CO-CULTURE. MULTIPLE P. AERUGINOSA STRAINS EXHIBITED ANTAGONISM, AND P. AERUGINOSA-MEDIATED ANTAGONISM WAS OBSERVED WITH ANOTHER NTM STRAIN, MYCOBACTERIUM SMEGMATIS. SURPRISINGLY, ANTAGONISM DID NOT REQUIRE KNOWN P. AERUGINOSA CONTACT-DEPENDENT OR -INDEPENDENT KILLING, MOTILITY, OR OXYGEN/IRON SEQUESTRATION MECHANISMS. THUS, WE HYPOTHESIZE THAT INTER- BACTERIAL ANTAGONISM OF M. ABSCESSUS BY P. AERUGINOSA IN DUAL-SPECIES BIOFILMS IS MEDIATED BY A NOVEL ANTIBACTERIAL STRATEGY. AIM 1 WILL UTILIZE SEVERAL COMPLEMENTARY STRATEGIES TO IDENTIFY THE MECHANISM OF INTERBACTERIAL ANTAGONISM. AIM 2 SEEKS TO INVESTIGATE M. ABSCESSUS AND P. AERUGINOSA INTERACTIONS UNDER CONDITIONS THAT CLOSELY MIMIC THOSE FOUND IN THE HOST. THE GROWING PREVALENCE OF M. ABSCESSUS INFECTIONS AND THEIR RECALCITRANCE TO BOTH HOST CLEARANCE AND ANTIBIOTICS HIGHLIGHT AN URGENT NEED TO FIND NEW STRATEGIES TO SUCCESSFULLY TREAT THESE PERSISTENT INFECTIONS. SUCCESSFUL COMPLETION OF THIS PROPOSAL WILL ADVANCE OUR UNDERSTANDING OF THE NOVEL P. AERUGINOSA ANTAGONISTIC MECHANISM TOWARDS M. ABSCESSUS BIOFILMS AND PROVIDE NOVEL BIOFILM TARGETS THAT COULD BE LEVERAGED TO AUGMENT ANTIMICROBIAL EFFICACY IN PEOPLE WITH INFLAMMATORY AND MUCO-OBSTRUCTIVE LUNG DISORDERS SUCH AS CF, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), AND NON-CF BRONCHIECTASIS AS WELL AS WITH OTHER NTM LUNG INFECTIONS SUCH AS MYCOBACTERIUM AVIUM.

Posted 5/21/24, 12:00 AM